MedPath

New Therapy of Laryngeal Papilloma In Children

Not Applicable
Terminated
Conditions
Papilloma
Interventions
Device: 585 nm pulsed dye laser
Dietary Supplement: diindolylmethane (DIM)
Registration Number
NCT00591305
Lead Sponsor
Boston University
Brief Summary

This study will determine efficacy of a new and combined treatment of laryngeal recurrent respiratory papillomatosis (RRP), by using a 585 nm pulsed dye laser (PDL) and a dietary supplement, diindolylmethane (DIM). We will compare this new treatment with PDL-only, in a total of 30 children (15 of each treatment), to determine whether this combined treatment would be effective and safe in preventing the RRP recurrence. This is the first study to combine PDL technique with DIM, to develop a new, voice-preserving and long-term effective method of managing laryngeal RRP in children.

Detailed Description

Previous studies have demonstrated that PDL can be used to remove lesions on the vocal cords and elsewhere in the throat causing less damage to surface tissues than other commonly used lasers. In our proposed clinical study, we seek to compare treatment efficacy for RRP by combining PDL with DIM, versus PDL-only treatment, in a total of 30 children with laryngeal papilloma. We will determine whether this combined treatment would be effective and safe in preventing or delaying the RRP recurrence while preserving voice quality. 30 children will be divided randomly into two treatment groups, 15 in each. The experimental group will receive one-time PDL treatment, followed by 3-month oral administration of DIM and an additional 12 months with no treatment. The other group will be treated with PDL-only, as a control, and take a placebo pill for 3 months. All of the patients will be followed for a total of 15 months. We will compare lesion recurrence and laboratory tests between the two groups, to determine efficacy and safety of the new treatment. This is the first study to combine new PDL laser technique with DIM, to develop a new, voice-preserving and long-term effective method of managing laryngeal RRP in children.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  1. 10 to 21 years of age
  2. laryngeal papillomas requiring surgical treatment
  3. willingness to participate in the study
  4. a signed informed consent form by guardian or parent
Exclusion Criteria
  1. age less than 10 year old, or older than 21 year
  2. guardian or parent does not understand or can not sign the consent form
  3. malignant diseases such as laryngeal cancer
  4. history of being hypersensitive to cabbage or other cruciferous vegetables
  5. pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PDL+placebo pill585 nm pulsed dye laseronce-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
PDL+DIM pilldiindolylmethane (DIM)once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
PDL+DIM pill585 nm pulsed dye laseronce-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
Primary Outcome Measures
NameTimeMethod
Number of Cases With Recurrence of Laryngeal Papilloma in 5 MonthsRecurrence of pailloma at 5 months

vocal lesion size and area after 5 month with surgery visible lesion found in \>50% of the treated tissue area, after surgery

Secondary Outcome Measures
NameTimeMethod
Estradiol Level in Blood Pre TreatmentBefore treatment at baseline

determine side-effect by comparing Estradiol level in blood before and after treatment

Estradiol Level in Blood Post Treatment5 month

determine side-effect by comparing Estradiol level in blood before and after treatment

Trial Locations

Locations (1)

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath